Vera Therapeutics Appoints James R. Meyers to Its Board of Directors
James R. Meyers was appointed to the Board of Directors of Vera Therapeutics as a Class II Director, effective November 25, 2025.
Meyers is a veteran biotech executive with extensive experience in commercial, public policy, and access strategies, relevant to Vera Therapeutics' growth stage.
He previously served as Executive Vice President at Gilead Sciences and was President and CEO of IntraBio Ltd. from 2020 to 2024.
Meyers currently serves on the Boards of Sangamo Therapeutics, Inc. and CytomX Therapeutics, Inc., and is a Senior Advisor at Boston Consulting Group.
Vera Therapeutics is preparing to launch atacicept, a potential first-in-class dual BAFF/APRIL inhibitor aimed to transform treatment for IgA nephropathy and other autoimmune diseases, scheduled for launch next year.
The appointment aligns with the company’s goal to support the anticipated launch of atacicept and its development in additional autoimmune disease areas.